Improving ovarian and lung cancer screening using blood immune markers
High-throughput immunoproteomics for cancer biomarker discovery
['FUNDING_OTHER'] · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · NIH-11180490
The project develops blood tests that look for immune system antibodies to help detect ovarian and lung cancers earlier in people at risk.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS (nih funded) |
| Locations | 1 site (SCOTTSDALE, UNITED STATES) |
| Trial ID | NIH-11180490 on ClinicalTrials.gov |
What this research studies
I’m part of a center at Arizona State University working to find immune signals in the blood that point to ovarian and lung cancer. We use high-throughput immunoproteomics and a systems immunology approach to search for three kinds of antibodies — anti-microbial antibodies, autoantibodies, and antibodies to abnormal glycoproteins — because these immune responses can reflect cancer-related protein changes. The team analyzes blood samples from multiple academic centers and builds multiplexed panels since combinations of markers give better predictive value. The group has prior blinded multicenter validation experience and has translated similar panels into a CLIA-certified blood test.
Who could benefit from this research
Good fit: Ideal participants are adults at increased risk for ovarian or lung cancer (for example, those with a family history, genetic risk factors, or a smoking history) or patients seen at participating academic medical centers who can provide blood samples.
Not a fit: People currently undergoing cancer treatment, pediatric patients, or those with unrelated medical conditions are unlikely to receive direct benefit from this biomarker-discovery project.
Why it matters
Potential benefit: If successful, this could produce blood tests that detect ovarian or lung cancer earlier or with fewer false alarms.
How similar studies have performed: Similar multiplexed autoantibody approaches have been confirmed in blinded phase 2 multicenter studies and led to a CLIA-certified commercial blood test, showing prior success with this strategy.
Where this research is happening
SCOTTSDALE, UNITED STATES
- ARIZONA STATE UNIVERSITY-TEMPE CAMPUS — SCOTTSDALE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LABAER, JOSHUA — ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
- Study coordinator: LABAER, JOSHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.